Back

Addition of sodium-glucose cotransporter-2 inhibitors on steroidal mineralocorticoid receptor antagonists eliminates hyperkalemia risk in diabetic heart failure patients with chronic kidney disease

17 May 2025 (16:00 - 16:45)
Organised by: Logo
Congress Presentation Part of: Congestion, SGLT2 inhibitors and novel therapies Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Associate Professor Anil Sahin

Canakkale 18 March University, Canakkale (Turkiye)

4 More presentations in this session

Presentation thumbnail
Optimisation of renin-angiotensin-aldosterone system inhibitors use in chronic kidney disease patients with heart failure: is hyperkalaemia a barrier?
Professor E. Kelepouris (Philadelphia, US)
Abstract Slides Video
Presentation thumbnail
Factors influencing the up-titration to 10 mg target dose of vericiguat: data from a large observational cohort-study in the US.
Doctor A. Michel (Basel, CH)
Abstract Slides Video
Presentation thumbnail
Introduction and optimization of the guideline-directed medical therapy in patients hospitalized for acute heart failure (OPTICARD)
Doctor G. Baudry (Nancy, FR)
Abstract Slides Video
Presentation thumbnail
The impact on CD146 congestion biomarker by early adding SGLT2i dapaglifozin to intravenous loop diuretic in patients with acute heart failure
Doctor I. Lala (Timisoara, RO)
Abstract Slides Video

Access the full session

Session thumbnail
Congestion, SGLT2 inhibitors and novel therapies

The Event

Event poster

Heart Failure 2025

17 May 2025 16:00 CET
You may be interested in
thumbnail
Congress Presentation
Initiation of mineralocorticoid receptor antagonists in patients with cardiorenal diseases: potassium changes, hyperkalaemia risk and discontinuation in the CaRe study
thumbnail
Congress Presentation
Discussant review - MRAs in heart failure
thumbnail
Congress Presentation
Hyperkalemia events in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan or sodium-glucose transport protein 2 inhibitors: a single-center experience

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources